Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy

Launched by UNIVERSITY HOSPITAL FREIBURG · Apr 14, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the best treatment options for elderly patients (aged 65 and older) with advanced head-and-neck squamous cell carcinoma (HNSCC), which includes cancers of the mouth, throat, and voice box. The researchers want to understand how effective different treatments, like modern radiotherapy and chemotherapy, are for these patients and whether these treatments can improve survival rates. They are specifically looking at the outcomes of patients who received these treatments between 2005 and 2019.

To be eligible for this study, participants must be at least 65 years old and have been diagnosed with locally advanced HNSCC that requires definitive treatment. However, those who have had previous head-and-neck cancers or certain types of metastases (cancer spread) are not eligible. If you or a loved one qualify, you can expect to contribute to important research that could help improve treatment for older adults facing this type of cancer. The trial is currently recruiting participants and aims to provide valuable insights that could shape future care for elderly patients with HNSCC.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • definitive (chemo-)radiotherapy of locoregionally advanced (cT3-4 and/or cN+) head-and-neck squamous cell carcinomas (HNSCC) of the oral cavity, oropharynx, hypopharynx or larynx
• • primary treatment since 2005
• • age ≥65 years at the time of (chemo-)radiotherapy
• Exclusion Criteria:
• • adjuvant (chemo-)radiotherapy
• • history of previous head-and-neck cancers or radiotherapy in the head-and-neck region
• • distant metastases at (chemo-)radiotherapy initiation (cM1)
• • HNSCCs of the nasopharynx, salivary glands, skin or with unknown primary